Failure Rate For Implantable Contraceptive Within Normal Range, Merck Says

In response to reports of adverse events in the United Kingdom, drugmaker Merck said on Wednesday that the number of unintended pregnancies associated with its long-acting contraceptive implant, Implanon, is not exceptional and that women should continue to use the method, the AP/Google News reports (AP/Google News, 1/5)…

Drug Industry Roundup: Fosamax Trial Focuses Scrutiny On Osteoporosis Drugs; What About $4 Generics; Recalls Undermining Confidence

The New York Times: A civil trial against the drugmaker Merck is now underway in Manhattan. A retired investigator for the U.S. army is one of 1,400 people suing the company on the premise that Fosamax, a Merck drug used by millions of women with thinning bones, caused them to develop jawbone ailments…

Beyaz(R): One Of The World's Leading Oral Contraceptive YAZ(R) Is Approved In The US With Metafolin(R)

Bayer Schering Pharma AG has been granted US Food and Drug Administration (FDA) approval for Beyaz®, the first oral contraceptive worldwide to contain folate, in the form of Merck & Cie’s Metafolin®. Metafolin® is the pure crystalline form of the naturally occurring active folate species, L-5-Methyltetrahydrofolate. Unlike folic acid, it can directly be used by the body…

Merck Submits Final Data For Application To Market HPV Vaccine Gardasil To Older Women

Merck on Wednesday announced that it has provided FDA with completed trial data on its human papillomavirus vaccine, Gardasil, in support of its application to market the vaccine to women ages 27 through 45, Reuters reports. FDA in 2006 approved Gardasil for girls and women ages nine through 26 to protect against certain strains of HPV that can lead to cervical cancer and genital warts…

Karo Bio Announces That Merck & Co., Inc. Plans To Proceed With Phase II Clinical Evaluation Of Candidate Compound

The Swedish biotech company Karo Bio (Reuters: KARO.ST) announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration’s lead investigational drug candidate, MK-6913, identified as part of their joint research collaboration. No milestone payment to Karo Bio is associated with the initiation of phase II clinical development.

Next Page »